Psyence Biomedical shares surge 25% after-hours following $3.5M follow-on investment in PsyLabs psychedelic API production.

Psyence Biomedical surged 25% in after-hours trading following its $3.5 million follow-on investment in PsyLabs, a producer of purified psychedelic active pharmaceutical ingredients. The strategic move, which aligns with growing interest in psychedelic-based therapies, signals PBM’s commitment to expanding its role in the emerging psychedelics market. By securing a reliable supply of APIs, the company aims to strengthen its pipeline for potential therapeutic applications, a development likely to enhance investor confidence. Both disclosed news events directly relate to the investment, confirming the alignment of the stock’s upward movement with the positive strategic news.